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Background: The aim of this study was to elucidate the value of putative cancer stem cell markers Musashi-1,
ALDH1, Sox2, and CD49f in predicting the prognosis in cervical squamous cell carcinoma (CSCC).
Methods: Real-time PCR and immunohistochemistry staining was performed to examine Musashi-1, ALDH1, Sox2,
and CD49f expression in archived specimens of CSCC patients with postoperative chemotherapy. Kaplan–Meier
analysis and Cox proportional hazards model were used to assess the prognostic impact of CSC markers for overall
survival (OS) and recurrent-free survival (RFS).
Results: The Real-time PCR data showed that the expression of all markers were increased in CSCC tissues
compared with in paired normal cervical tissues (P < 0.05). The IHC result showed that high expression of Msi1,
ALDH1, Sox2, and CD49f was found in 25.7 %, 43.0 %, 62.0 % and 29.0 % CSCC samples, respectively. Moreover,
high expression of Msi1 (P = 0.033 and P = 0.003, respectively), ALDH1 (P = 0.015 and P = 0.002, respectively), and
Sox2 (P = 0.005 and P = 0.003, respectively), and low expression of CD49f (P = 0.027 and P = 0.025, respectively) were
correlated with poor OS and PFS in CSCC patients. Interestingly, tumors with Msi1high/CD49flow expression had the
poorest prognosis according to Msi1/CD49f stratification. In multivariate Cox regression analysis, Sox2 expression
(P = 0.047 and P = 0.018, respectively), ALDH1 expression (P = 0.013 and P = 0.003, respectively), and CD49f
expression (P = 0.008 and P = 0.003, respectively) were independent prognostic markers for both OS and RFS.
Conclusions: Our results suggest that cancer stem cell markers are linked with poor prognosis of CSCC patients.
Keywords: Cervical squamous cell carcinoma, Cancer stem cell, Prognosis, Chemoresistance, Musashi-1, ALDH1,
Sox2, CD49fBackground
Cervical cancer is the second most common gynecologic
cancer in developing countries, with over 500,000 new
cases and 274,000 deaths annually [1]. Despite advances
in surgical capabilities and chemotherapy strategies, a
substantial proportion of patients still die from recurrent
or chemoresistant disease. Approximately 30–50 % of
advanced-stage patients will develop recurrent disease [2].
Even in patients with early-stage disease, 10–20 % will* Correspondence: zhangyannapds@126.com
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treatment. The reported median overall survival time of
patients who recur after radical surgery or radiotherapy
are between 7 and 12 months [3]. Adjuvant platinum-
based drugs are standard chemotherapy treatment for cer-
vical cancer. Meanwhile, the duration for response to
chemotherapy in patients with recurrent diseases remains
disappointing.
Currently, there is a lack of biomarkers for predicting
the response to chemotherapy in cervical cancer patients.
Cancer stem cells (CSCs) are defined as a small popu-
lation of cells within a tumor that can self-renew and
drive tumorigenesis. Increasing evidence has suggested
that CSCs are naturally resistant to chemotherapeuticdistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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following chemotherapy [4]. The potential mechanisms
of CSC resistance to chemotherapy include slow cell
cycle kinetics, overexpression of DNA repair proteins
and multidrug resistance transporters, and protection by
hypoxic niches [5].
It is postulated that CSCs may originate from normal
stem cells and express the same cell markers as normal
stem cells. Such a model has been proposed for cervical
CSC markers as well [6]. To date, several potential cervical
epithelial stem cell markers including Musashi-1 (Msi1),
ALDH1, SOX2, and CD49f have been used to identify cer-
vical CSCs (CCSCs). Musashi-1 is a RNA-binding protein
to regulate the proliferation of multipotential stem/pro-
genitor cells and the proliferative activity of tumor cells
[7]. This protein may also have roles in cervical carcino-
genesis [8]. ALDH1 is a polymorphic enzyme involved in
oxidation of aldehydes to carboxylic acids. It has been re-
ported to enhance the self-renewal and differentiation po-
tentials of cervical cancer cells [9]. Sox2 is essential for the
formation of many different tissues and organs during em-
bryonic development. Sox2-positive population of cervical
cancer cells show characteristics of tumor-initiating cells.
Its expression increases the expression of CSC markers,
the potential to form tumor spheres, and the tumor initi-
ating capacity of cervical cancer cells [10]. CD49f gene
encodes an integral cell-surface protein that has been pro-
posed to play a role in cell adhesion as well as in cell-
surface mediated signaling. CD49f has been used as an
epithelial stem cell marker and was recently found highly
expressed on cervical cancer-initiating cells [11].
As CSCs are thought to be responsible for tumor che-
moresistance and recurrence, the evaluation of CSC
markers expression in cervical cancer could highlights
the mechanisms underlying cervical cancer progression
and recurrence. Moreover, to determine the association
of CSC markers expression to cervical cancer chemore-
sponsiveness could help in the development of targeted
agents to treat chemoresistant disease. The aims of this
work were therefore to evaluate the expression pattern
of Msi1, ALDH1, Sox2, and CD49f in cervical cancer tis-
sues and to determine their significance in predicting
the prognosis in cervical cancer patients.
Methods
Patients and tissue specimens
A total of 179 cervical cancer patients treated between
January 2001 and December 2008 were included in the
study. The material was retrieved from archival paraffin-
embedded surgical samples at Sun Yat-Sen University
Cancer Center. In addition, 75 pairs of snap-frozen cer-
vical cancer and normal cervical samples from above pa-
tients were collected for Real-time PCR. None of the
patients had received chemotherapy or radiotherapy beforesurgery. After surgery, the patients were treated with adju-
vant chemotherapy according to the national guidelines.
Platinum-based chemotherapy was initiated within two
weeks after surgery and then repeated for four cycles at
three-week intervals. In all cases, the diagnoses and grad-
ing were peer-reviewed according to the principles laid
down in the latest International Federation of Gynecology
and Obstetrics criteria [12]. Prior written consent was ob-
tained from all patients and this study was approved by
the Research Ethics Committee of Sun Yat-Sen University
Cancer Center.
RNA extraction and real-time PCR
Total RNA from CSCC and paired normal cervical tissues
was extracted using Trizol reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions.
The extracted RNA was pretreated with RNase-free
DNase, and 2 μg RNA from each sample was used for
cDNA synthesis with random hexamers. Real-time PCR
was performed using the Applied Biosystems 7500 Se-
quence Detection system. The primers used are as follows:
Msi1, forward, 5’- GAGGGTTCGGGTTTGTCACG-3’,
reverse, 5’-GGCGACATCACCTCCTTTGG-3’; ALDH1,
forward, 5’-GTTAGCTGATGCCGACTT GG-3’ , reverse,
5’-CCCACT CTCAATGAGGTCAAG-3’; Sox2, forward,
5’- GCTGTATGGCTGCTGCACTTC-3’, reverse, 5’-GCA
CACGCACCCAGCACT GT-3’; CD49f, forward, 5’- ATG
GAG GAAACCCTGTGGCT-3’, reverse, 5’- ACGAGAGC
TTGG CTCTTG GA-3’; GAPDH, forward, 5’-AGAAG
GCTGGGCTCATTTG-3’, reverse, 5’-AGGGGCCATCCA
CAGTCTTC-3’. The expression level of CSC markers
mRNA was calculated using a ratio of CSC markers mRNA
to GAPDH mRNA.
Immunohistochemical (IHC) staining
Immunostaining was performed on paraffin-embedded
4 μm sections and mounted on poly-L-lysine-coated
slides. The sections were baked at 65 °C for 30 minutes,
then deparaffinized in xylene and rehydrated. Antigen
retrieval was performed by submerging the sections into
a 10 μmol/L citrate buffer solution (pH 6.0) for 10 mi-
nutes in a microwave oven. The slides were then treated
with 3 % hydrogen peroxide in methanol to quench the
endogenous peroxidase activity, followed by incubation
with 1 % fish skin gelatin to block the nonspecific staining.
Tissue sections were incubated overnight with monoclo-
nal rabbit antibody against Msi1 (Abcam, Cambridge,
USA; 1:200), monoclonal rabbit antibody against ALDH1
(Abcam, Cambridge, USA; 1:200), monoclonal mouse
antibody against Sox2 (Abcam, Cambridge, USA; 1:200),
and monoclonal rabbit antibody against CD49f (Abcam,
Cambridge, USA; 1:200). After washing, the sections were
incubated with prediluted secondary antibody (Abcam,
Cambridge, USA), followed by further incubation with
Table 1 Clinicopathological characteristics















≤4 cm 120 67.0
>4 cm 59 33.0
Total No. of Patients 179 100
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the slides were counterstained with hematoxylin and
mounted in an aqueous mounting medium.
For negative controls, primary antibodies were replaced
with normal serum.
IHC score
Immunostaining was separately evaluated by two inde-
pendent pathologists who were blinded as to the patients.
Expression of the four CCSC markers was analyzed by an
individual labeling score considering percent and staining
intensity of positive cells. Intensity of stained cells was
graded semi-quantitatively into four levels: 0 (no staining);
1 (weak staining = light yellow); 2 (moderate staining = yel-
low brown) and 3 (strong staining = brown); and the per-
centage was scored as: 0, negative; 1, 10 % or less; 2, 11 %
to 50 %; 3, 51 % to 80 %; or 4, 80 % or more positive cells.
Intensity and fraction of positive cell scores were multi-
plied for each marker and thus the scoring system was
defined as low expression for scores of 0–3, and as high
expression for scores of 4–12.
Statistical analysis
All statistical analyses were carried out using SPSS (ver-
sion 16.0, SPSS Inc, Chicago, USA) statistical software.
The overall survival (OS) and recurrence-free survival
(RFS) were calculated as the time from the date of primary
surgery to the date of first death or recurrence. Survival
curves were plotted using the method of Kaplan-Meier,
and the log-rank test was used to determine statistical dif-
ferences between life tables. The correlations between
clinicopathologic characteristics and recurrence were ana-
lyzed using the χ2 test. Univariate and multivariate analysis
were applied to assess the independent predictive signifi-
cance of variables on RFS. P < 0.05 in all cases was consid-
ered statistically significant.
Results
Clinical results and tumor recurrent
Patients’ clinicopathological characteristics were shown in
Table 1. In total, 179 cervical cancer patients with up to
stage IIB were investigated. The median follow-up period
of the patients was 48.8 months (range 1.6–60.0 months).
After postoperative chemotherapy, 22 patients had recur-
rent disease.
Patterns of expression
To investigate the potential roles of CSC markers in the
development of cervical cancer, we determined the ex-
pression of Msi1, ALDH1, Sox2 and CD49f in 179
paraffin-embedded cervical carcinoma samples by im-
munohistochemistry. Msi1 immunoreactivity was both
cytoplasmic and nuclear and high expression was ob-
served in 46 cases (25.6 %). ALDH1 immunoreactivitywas cytoplasmic and high expression was observed in 77
cases (43.0 %). Sox2 immunoreactivity was nuclear and
high expression was observed in 111 cases (62.0 %).
CD49f immunoreactivity was both membranous and cyto-
plasmic and high expression was observed in 52 cases
(29.0 %). The representative immunostaining of Msi1
(Fig. 1a–b), ALDH1 (Fig. 1c–d), Sox2 (Fig. 1e–f ) and
CD49f (Fig. 1g–h) were shown in Fig. 1. Moreover, Real-
time PCR showed that the expression level of all CSC
markers was increased in CSCC compared with that in
normal cervical tissues (Fig. 2).
Associations between Msi1, ALDH1, Sox2 and CD49f
expression and clinicopathological features
The expression of CCSC markers was evaluated in rela-
tion to clinicopathological variables for cervical cancer.
Msi1, ALDH1, and Sox2 expression were positively cor-
related with tumor recurrence (P = 0.005, P = 0.003, and
P = 0.003, respectively), while CD49f expression was
negatively correlated with tumor recurrence (P = 0.028)
(Table 2). Msi1, ALDH1 and CD49f expression was not
associated with any of the clinicopathological variables,
while only Sox2 expression was significantly associated
with tumor size (P = 0.010). (Additional file 1: Table S1).
Associations between Msi1, ALDH1, Sox2 and CD49f
expression and clinical prognosis
To examine the prognostic value of CSCs markers in
cervical cancer, we evaluated the correlation between
Msi1, ALDH1, Sox2 and CD49f expression and progno-
sis in CSCC patients. Notably, high expression of Msi1
Fig. 1 The expression of Msi1, ALDH1, CD49f, and Sox2 in cervical squamous cell carcinoma by immunohistochemistry. a and b, high and low
immunoreactivity of Msi1. c and d, high and low immunoreactivity of ALDH1. e and f, high and low immunoreactivity of CD49f. g and h, high
and low immunoreactivity of Sox2. (original magnification 400×)
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and P = 0.002, Fig. 3c and d), and Sox2 (P = 0.005 and
P = 0.003, Fig. 3e and f ), and low expression of CD49f
(P = 0.027 and P = 0.025, Fig. 3a and d) were correlated
with poor OS and RFS in all the 179 CSCC patients
who received postoperative adjuvant chemotherapy.
Moreover, double stratification analysis of OS and RFS
according to Msi1/CD49f, ALDH1/CD49f, and Sox2/
CD49f were performed and shown in Fig. 4. Tumors with
Msi1high/CD49flow, ALDH1high/CD49flow, and Sox2high/
CD49flow expression had a poorer prognosis com-
pared with those with Msi1low/CD49fhigh (P = 0.002
and P < 0.001, Fig. 4a and b), ALDH1low/CD49fhigh
(P = 0.008 and P = 0.002, Fig. 4c and d), and Sox2low/
CD49flow expression (P = 0.006 and P = 0.005, Fig. 4e
and f ), respectively.
Univariate and multivariate Cox proportional hazards re-
gressions analysis were also applied. Univariate analysis
showed that FIGO stage, tumor size, and Msi1 expression
were significantly correlated with both OS and RFS. The
ALDH1 expression, Sox2 expression, and CD49f expression
were significantly associated with RFS (data not shown).
Multivariate analysis showed that FIGO stage > IB1
(P = 0.002 and P = 0.005, respectively), high Sox2 expression
(P = 0.047 and P = 0.018, respectively), high ALDH1 expres-
sion (P = 0.013 and P = 0.003, respectively), and low CD49fFig. 2 Relative mRNA expression of Msi1, ALDH1, Sox2, and CD49f in normexpression (P = 0.008 and P = 0.003, respectively) were inde-
pendent prognostic factors for both OS and RFS (Table 3).
Discussion
CSCs are generally thought to arise from normal stem
cells that have developed genetic mutations over time.
CCSCs could arise from Müllerian duct-derived cervical
stem cells located in the basal layer of the ectocervical
squamous or endocervical columnar epithelium [13].
These cells have been proposed to drive the resistance
to chemotherapy through the expression of drug efflux
pumps in normal stem cells from which they were de-
rived [14]. Therefore, the identification of the CSCs sub-
population of tumor cells may offer new directions for
the treatment of cervical cancer. In the present work, we
provide the first link between the expression of four pu-
tative CCSC markers and the clinical outcome in cer-
vical cancer patients.
Previous studies have demonstrated that CSCs are re-
sponsible for the high rate of chemoresistance and tumor
relapse. The possible mechanisms of chemoresistance
include high expression levels of adenosine triphosphate-
binding cassette transporters, low self-renewal rate, an
active DNA repair capacity, and activated Wnt/β-catenin
and Notch signaling [15]. Clinical and experimental stud-
ies have provided evidence of the relationship betweenal cervical and CSCC tissues. * P < 0.05
Table 2 Association of cancer stem cell markers expression and
tumor recurrence
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Grade 3 16(72.7) 92(58.6)
Timor Size 0.069
≤4 cm 11(50.0) 109(69.4)













Fig. 3 Kaplan–Meier estimated of overall survival and recurrence-free surviv
a Overall survival and b recurrence-free survival time differences in patients
recurrence-free survival time differences in patients with low vs high expre
differences in patients with low vs high expression of Sox2. g Overall surviv
vs high expression of CD49f
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peutic drugs. Manohar et al. proposed that overexpression
of MYCN, the most widely characterized gene associated
with poor outcome of neuroblastoma, resulted in in-
creased drug resistance and expression of MRP1, suggest-
ing that MRP1 may be a MYCN target gene involved in
the drug-resistance phenotype of neuroblastoma [16].
Wang et al. reported that overexpression of caveolin-1 en-
hanced chemoresistance of breast CSCs, which could be
prevented by downregulation of the β-catenin/ABCG2
pathway [17]. Recent studies also implicated CSCs in cer-
vical cancer chemoresistance [18], while there is lack of
data concerning the relevance of the expression of CSC
markers with clinical prognosis and chemosensitivity in
cervical cancer. Our findings suggest that the expression
of CSC markers Msi1, ALDH1, Sox2, and CD49f were
increased in CSCC tissues and that their expression are
linked to clinical survival in cervical cancer patients under-
going postoperative chemotherapy, suggesting an import-
ant role of these markers in predicting clinical prognosis
in cervical cancer. Surprisingly, we found that the expres-
sion of CSC markers showed no association with age,
tumor stage, tumor size, or tumor differentiation, while
only Sox2 expression was significantly correlated with
tumor size. The results may be due to small group size.
ALDH1 has long been thought to be a CSC marker
and has also been described to be associated with tumor
progression and recurrence [19]. Many recent studies in-
vestigating the ALDH1 gene or protein report its impact
on the clinical outcome of patients with malignancies.
Dylla et al. reported that the inherent chemotherapeutical according to putative stem cell markers expression in CSCC patients.
with low vs high expression of Msi1. c Overall survival and d
ssion of ALDH1. e Overall survival and f recurrence-free survival time
al and h recurrence-free survival time differences in patients with low
Fig. 4 Kaplan–Meier estimates of overall survival and recurrence-free survival according to combinations of putative stem cell markers. a Overall
survival and b recurrence-free survival according to Msi1 and CD49f expression. c Overall survival and d recurrence-free survival according to
ALDH1 and CD49f expression. e Overall survival and f recurrence-free survival according to Sox2 and CD49f expression
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enzymatic activity [20]. Alamgeer et al. described ALDH1
as a useful predictor of chemoresistance in locally ad-
vanced breast cancer [21]. Our present investigation found
that high ALDH1 expression was an independent pre-
dictor of recurrence and overall survival in CSCC patients.
Among patients with high ALDH1 expression, 21 % had
recurrent cancer, whereas only 6 % patients with low
ALDH1 expression did. Our study is supported by Deng
et al., who demonstrated that high residual ALDH1 ex-
pression after radiochemotherapy significantly predicted
tumor metastasis or recurrence [22]. The same finding
was also applied for another potential CCSC marker Sox2.Table 3 Multivariate analysis of overall and recurrence–free survival
Prognostic variables Overall survival
Hazard ratio (95 % CI)
Age (>40 vs ≤40)
FIGO Stage (>IB1 vs IB1) 7.467 (2.107–26.460)
Differentiation (Grade 3 vs 1/2)
Timor Size (>4 cm vs ≤4 cm)
Msi1 (high vs low)
ALDH1 (high vs low) 3.805 (1.331–10.879)
CD49f (high vs low) 0. 064 (0.008–0.492)
Sox2 (high vs low) 8.650 (1.141–65.603)It has recently been linked with enhanced chemoresis-
tance and tumorigenecity of gastric cancer derived cancer
stem-like cells [23]. Conversely, suppression of Sox2 can
impair the chemosensitivity and stemness of cancer cells
[24]. In the present study, we found that up-regulation of
Sox2 predict poor overall and recurrence-free survival in
CSCC patients. Among patients with high Sox2 expres-
sion, 18 % had recurrent cancer, whereas only 3 % patients
with low Sox2 expression did, implicating a correlation of
Sox2 expression and cervical cancer progression. Rela-
tively fewer studies have evaluated the roles of Msi1 in
chemoresistance. Li et al. identified a population of che-
moresistant SP cells from gastric cancer cell line andRecurrence–free survival
P Hazard ratio (95 % CI) P
0.002 3.938 (1.524–10.197) 0.005
0.013 4.261 (1.655–10.968) 0.003
0.008 0.108 (0.025–0.470) 0.003
0.047 5.834 (1.353–25.163) 0.018
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[25]. Johannessen et al. demonstrated that the expression
of Msi1 was downregulated through inhibition of PI3K/
AKT pathway, which is involved in treatment resistance in
glioblastomas [26]. In this study, we document a poorer
overall and recurrence-free survival time with high expres-
sion of Msi1 in univariate but not multivariable survival
time analysis, indicating that the poor prognostic role of
Msi1 may be secondary to their association with other
established prognostic criteria. Altogether, these studies
suggest that increased ALDH1, Sox2, and Msi1 expression
are related to the progression and may be related to che-
moresistance of CSCC.
Interestingly, we found that CD49f expression was in-
creased in CSCC tissues while high expression of CD49f
was associated with favourable prognosis of patients.
The results suggested that CD49f expression was linked
with reduced chemoresistance in cervical cancer. CD49f
has been reported to play a critical role in CSC mainten-
ance and in the attachment of tumor cells to laminin
[27]. The unexpected finding that CD49f expression was
correlated with better clinical outcome suggests that not
all CSC markers characterise the chemoresistant cell
population and that the prognostic role of CD49f might
be tissue specific and diverse in different cancers. An-
other explanation is that the expression of CD49f may
be decreased in the invasive area of cancer tissues, which
has already been reported for other cell adhesion mole-
cules, and which has been regarded as a key event in
epithelial mesenchymal transition [28].
An important finding emerges from the present investi-
gation is that tumors with high Msi1 and low CD49f ex-
pression had the poorest prognosis, whereas tumors with
lack of Msi1 and CD49f overexpression had the best prog-
nosis. Double stratification analysis was also performed
according to ALDH1/CD49f, and Sox2/CD49f, and the re-
sults showed that ALDH1high/CD49flow and Sox2high/
CD49flow population predict poor recurrent-free prognosis
in CSCC patients. The results imply the importance of
such a sub-population in predicting the prognosis and
chemosensitivity of cervical cancer patients. Targeting this
cell population with novel pharmaceutical agents may
prove to be effective for the treatment of chemoresistant
cervical tumors.
Conclusions
In conclusion, our study provided the first clinical evi-
dence that CSC markers are associated with the clinical
prognosis of CSCC patients. High expression of Msi1,
ALDH1, and Sox2, and low expression of CD49f predict
poor prognosis for cervical cancer patients receiving
postoperative chemotherapy. Moreover, double stratifi-
cation analysis showed that Msi1high/CD49flow subgroup
had the poorest RFS. Our findings may be of great valuein the development of personalized therapies for patients
with cervical cancer.
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